Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 227,741,300 papers from all fields of science
Search
Sign In
Create Free Account
Low Molecular Weight Cyclin E
Known as:
LMW-E
Proteolytically processed forms of cyclin E proteins, which are specifically generated in tumors that overexpress cyclin E proteins.
National Institutes of Health
Create Alert
Alert
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
Cytoplasmic Cyclin E is an Early Event for Progression to Invasive Breast Cancer
2017
Corpus ID: 52253422
As depicted in this figure, we have discovered that the LMW-E isoforms are potent oncogenes that act early in the etiology of…
Expand
2016
2016
Abstract 2989: An Intact G1/S checkpoint determines response to CDK4/6 inhibitor in breast cancer
S. Vijayaraghavan
,
K. Keyomarsi
2016
Corpus ID: 79209698
Deregulation of the cell cycle machinery is a hallmark of most cancers, making the positive regulators of cell cycle such as…
Expand
2015
2015
Abstract 3171: IL-25/IL-17E does not induce breast tumor cell apoptosis and both IL-17A and IL-25/IL-17E contribute to breast cancer survival and proliferation associated with generation of pro…
J. Giustiniani
,
H. Curé
,
+6 authors
A. Bensussan
2015
Corpus ID: 74383368
Pro-inflammatory IL-17 cytokines were initially described for their pathogenic role in chronic inflammatory diseases and…
Expand
2015
2015
Abstract 1783: Pharmacological inhibition of CDK4/6 induces G1 arrest, autophagy and senescence in ER+ breast cancer
S. Vijayaraghavan
,
K. Keyomarsi
2015
Corpus ID: 79028431
Proceedings: AACR 106th Annual Meeting 2015; April 18-22, 2015; Philadelphia, PA Deregulation of the cell cycle machinery is a…
Expand
2015
2015
Abstract P5-08-02: Inhibition of CDK4/6 induces senescence and autophagy in ER positive breast cancers
S. Vijayaraghavan
,
K. Keyomarsi
2015
Corpus ID: 69102401
Deregulation of the cell cycle machinery is a hallmark of breast cancer, facilitating aberrant proliferation that fuels…
Expand
2015
2015
Abstract 3772: Cyclin E as a prognostic marker and predictor of response to neoadjuvant chemotherapy and adjuvant hormonal therapy in patients with stage II-III breast cancer
Cansu Karakas
,
A. Francis
,
M. Yi
,
A. Sahin
,
K. Keyomarsi
,
K. Hunt
2015
Corpus ID: 79237817
Purpose: While we know that many cytotoxic chemotherapeutic agents act to modulate the cell cycle, the role of cyclin E as a…
Expand
2014
2014
A phase 1 study of dinaciclib (SCH 727965) in combination with epirubicin in patients with metastatic triple-negative breast cancer.
Kansu Karakas
,
N. Ibrahim
,
+5 authors
S. Moulder
Journal of Clinical Oncology
2014
Corpus ID: 20574360
163 Background: Low molecular weight cyclin E (LMW-E) isoforms are overexpressed in a majority (~70%) of triple-negative breast…
Expand
2013
2013
Abstract P6-12-09: Targeting deregulated cyclin E in inflammatory breast cancer via sequential combination therapy
Angela Alexander
,
Cansu Karakas
,
Yilei Gong
,
R. Alvarez
,
N. Ueno
,
K. Keyomarsi
2013
Corpus ID: 71216732
Inflammatory breast cancer (IBC) is a rare, highly aggressive form of breast cancer, accounting for 2-5% of all breast cancers in…
Expand
2012
2012
Too Much Cleavage of Cyclin E Promotes Breast Tumorigenesis
K. Loeb
,
Xueyan Chen
PLoS Genetics
2012
Corpus ID: 14533746
Cyclin E, together with cyclin-dependent kinase 2 (CDK2), functions as a gatekeeper to promote G1/S transitions and the…
Expand
2011
2011
P5-03-01: Cytoplasmic Cyclin E and P-CDK2 Expression in Triple Negative Breast Carcinomas Measured by Immunohistochemistry Correlates with Poor Outcome.
A. Biernacka
,
Cansu Karakas
,
+4 authors
K. Khandan
2011
Corpus ID: 76078659
Background: Triple negative breast carcinomas (TNBCs) are aggressive malignancies that lack effective therapeutic targets but…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE